Navigation Links
Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference

FORT WORTH, Texas, Jan. 5, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that Travis E. Baugh, President and Chief Operating Officer, and Robert Bancroft, Executive Vice President, Strategic and Commercial Development, will present an overview of the Company, its commercial products and its R&D pipeline at the upcoming J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 9th, at 9:30 am (PST) at the Westin St. Francis Hotel in San Francisco, CA.

The presentation will include updates on the Company's ongoing commercial operations and phase 3 plans for its cell therapy pipeline candidate for venous leg ulcers (HP802-247).

About Healthpoint Biotherapeutics

Healthpoint Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for dermal repair and regeneration. The company's research and development strategy is presently centered around next-generation cell-based therapies for the treatment of chronic wounds. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix, OASIS® Ultra Tri-Layer Matrix and REGRANEX® Gel. Healthpoint Biotherapeutics is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from The Wound Institute®. To learn more about this comprehensive and award winning educational resource, please visit®. Healthpoint Biotherapeutics is a DFB Pharmaceuticals, Inc., affiliate company, and is based in Fort Worth, Texas. For more information, visit the company website at


OASIS is a registered trademark of Cook Biotech, Inc.


SOURCE Healthpoint Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
2. Healthpoint Biotherapeutics Acquires Regranex® Gel
3. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
4. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
5. Northwest Biotherapeutics Announces Change and Expansion of Management Team
6. Northwest Biotherapeutics Announces Series of Financing Arrangements
7. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
8. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
9. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
10. Talecris Biotherapeutics Announces First Quarter 2011 Results
11. Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
Post Your Comments:
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an ... is bound to proteins, copper is also toxic to cells. With a $1.3 ... Institute (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas ...
(Date:11/24/2015)... Nov. 24, 2015  Clintrax Global, Inc., a worldwide provider of ... , today announced that the company has set a new quarterly ... quarter on quarter growth posted for Q3 of 2014 to Q3 ... Mexico , with the establishment of an ... --> United Kingdom and ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), ... MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing ... AMA members have embraced this type of racing and several new model aviation pilots ...
Breaking Biology Technology:
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):